TITLE

DICERNA/IPSEN TO DEVELOP ENDOCRINOLOGY/ONCOLOGY THERAPEUTICS

PUB. DATE
May 2010
SOURCE
Worldwide Biotech;May2010, Vol. 22 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an exclusive research collaboration agreement between Dicerna Pharmaceuticals Inc. and global biotechnology specialty care group Ipsen. Under the partnership, the two firms are planning to develop novel conjugates of the Dicer Substrate small interfering ribonucleic acid (siRNA) molecules and the peptide targeting vectors of Ipsen in endocrinology and oncology therapeutics. Both Dicerna chief executive officer (CEO) and co-founder James C. Jenson and Claude Bertrand of Ipsen acknowledge the significance of such a collaboration.
ACCESSION #
49761082

 

Related Articles

  • Dicerna seeks $69m, Uniqure $75m as biotech IPO-palooza rolls on. Powers, Marie // BioWorld Today;1/3/2014, Vol. 25 Issue 2, p1 

    The article reports on the decision of Dicerna Pharmaceuticals Inc. to join Revance Therapeutics Inc. to seek for an extension of its initial public offering (IPO) in 2014. Dicerna is aiming to raise up to 69 million dollars to advance its next-generation RNAI pipeline, based on optimized Dicer...

  • Dicerna Raises $25M Series B to Fund RNAi Cancer Program. Shaffer, Catherine // BioWorld Today;8/12/2010, Vol. 21 Issue 155, p1 

    The article reports on the Series B financing raised by Dicerna Pharmaceuticals Inc. amounting to 25 million U.S. dollars for the advancement of preclinical ribonucleic acid interference (RNAi) oncology program to the clinical trial stage. Considering itself as a platform-to-product company,...

  • Dicerna, Kyowa $1.4B Pact Called Largest Target-Based RNAi Deal. Young, Donna // BioWorld Today;1/5/2010, Vol. 21 Issue 2, p1 

    The article reports on the partnership between Dicerna Pharmaceuticals Inc. and Kyowa Hakko Kirin Co. Ltd. (KHK), a Japanese biopharmaceutical firm, for the development and commercialization of drug delivery systems and small interfering RNA (siRNA) medications based on the Dicer Substitute...

  • Dicerna Pharmaceuticals Announces 2nd DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Dicerna Pharmaceuticals Inc. in collaboration with Kyowa Hakko Kirin Co. Ltd. has recognized the successful achievement of an in vivo activity milestone in the development of its second collaborative therapeutic oncology candidate. The candidate was developed utilizing...

  • GSK/Galapagos: together on a voyage of discovery.  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p21 

    The article reports on the alliance formed by Galapagos with GlaxoSmithKline PLC to discover drug targets in asthma and allergy. This collaboration will take advantage of the small interfering RNA based adenovirus discovery technology of Galapagos. Currently, an inhaled steroid combined with a...

  • Dicerna Raises $25M for RNAi Cancer Program.  // Bioworld Week;8/16/2010, Vol. 18 Issue 33, p4 

    The article reports that Dicerna Pharmaceuticals Inc. has raised 25 million dollars for the clinical trials of its RNAi oncology research program.

  • Impact of siRNA transfection on tumor development under experimental pathology of thyroid gland. Zaporozhan, V. M.; Maryniuk, G. S.; Kholodkova, O. L.; Bubnov, V. V.; Andronov, D. U. // Biopolymers & Cell;2013, Vol. 29 Issue 6, p463 

    Aim. To assess the impact of siRNA transfection on the tumor development under experimental pathology of the thyroid gland. Methods. Experiments were performed on rats weighing 180± 20 g, which were divided into five groups: IA and IB - animals with simulated hypo- and hyperthyroid states and...

  • Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update. Folini, M.; Pennati, M.; Zaffaroni, N. // Medicinal Chemistry Reviews - Online;Oct2004, Vol. 1 Issue 4, p413 

    Human telomerase is a ribonucleoprotein enzyme complex that, when expressed at high level, enables cells to maintain telomere length, allowing indefinite replicative capacity. The notion that telomerase is reactivated in 80–90% of human cancers has led to the proposal of telomerase as a...

  • Poly(oligo-D-arginine) With Internal Disulfide Linkages as a Cytoplasm-sensitive Carrier for siRNA Delivery. Young-Wook Won; Sun-Mi Yoon; Kyung-Mi Lee; Yong-Hee Kim // Molecular Therapy;Feb2011, Vol. 19 Issue 2, p372 

    Small interfering RNA (siRNA) has emerged as a therapeutic strategy for various diseases due to its target-specific gene silencing; however, its relatively high molecular weight, negative charge, and low stability hamper in vitro and in vivo applications. Approaches to overcome those drawbacks...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics